Gilead Sciences Stock Falls Despite HIV Drug Yeztugo Beating Q2 Expectations

3-line summary

• Gilead Sciences' HIV prevention drug Yeztugo beat second-quarter expectations, easing concerns over soft prescription trends, but the stock fell on Wednesday, according to the report.
• Analysts focused instead on the company's existing HIV treatments Biktarvy and Descovy, which also beat estimates, aided by pricing, inventory and seasonal dynamics.

This summary is our own processing of the source article; see the source link below for full context.